Updated:
Talphera
Talphera, originally incorporated as AcelRx Pharmaceuticals in 2005, rebranded in early 2023 under CEO Vincent Angotti to signal a strategic pivot.
Talphera
Talphera, originally incorporated as AcelRx Pharmaceuticals in 2005, rebranded in early 2023 under CEO Vincent Angotti to signal a strategic pivot. The predecessor company developed DSUVIA, a 30 mcg sufentanil sublingual tablet delivered via a single-dose applicator, cleared by the FDA in 2018 for acute pain severe enough to require an opioid analgesic in medically supervised settings. The wealth origin is irrelevant — Talphera is a public company traded on Nasdaq under the ticker TLPH, with no founding family or single-family-office capital structure. The firm's strategy now balances commercial monetization with clinical development. DSUVIA sales to the Department of Defense and military treatment facilities provided early revenue through a contract with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. On the pipeline side, Niyad — a nafamostat mesylate regional anticoagulant for the dialysis circuit — received Breakthrough Device Designation from the FDA. Talphera funded Niyad's registrational study partly through a royalty-backed financing agreement with XOMA (US) LLC, which provided up to $10 million in 2023 in exchange for a tiered royalty on DSUVIA and Niyad commercial sales. The company also terminated its legacy European commercialization agreement for DZUVEO, reclaiming territory rights. The company maintains a lean operational footprint. As of early 2024, headcount had contracted following the discontinuation of the commercial field force in 2022, with the remaining team focused on regulatory and business development activities from its San Mateo headquarters. Adjacent vehicles do not apply; the firm holds no venture-capital or philanthropic-entity structures. In September 2023, Talphera effected a 1-for-18 reverse stock split to regain Nasdaq listing compliance, a move that compressed its public float while preserving access to capital markets. Talphera's structural differentiator is its near-absence of dilutive equity financing risk for the Niyad program. Unlike most micro-cap biotechs, its clinical asset is funded by a royalty-based facility, not periodic capital raises. The FDA device designation for Niyad also grants expedited review. This pair of regulatory and financial underwriting features isolates Talphera from a cohort of opioid-therapy peers that remain tied to a widely stigmatized prescribing environment — DSUVIA's single-dose, supervised-use profile avoids outpatient dispensing risk, and Niyad targets a device-based indication with no addiction liability.
General information
Firm type
Asset Manager
Year founded
2005
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Mateo
Corporate office
San Mateo, CA, United States
Principals
Vincent J. Angotti
Chief Executive Officer
Sector focus
Frequently asked questions
What is Talphera's primary commercial asset?
DSUVIA (sufentanil sublingual tablet 30 mcg) is Talphera's FDA-approved product for acute pain management in medically supervised settings. It is delivered via a pre-filled, single-dose applicator and is stocked by military treatment facilities under a longstanding Department of Defense procurement relationship. The drug is not dispensed for outpatient use.
How is Talphera's pipeline funded without recurring equity raises?
Talphera secured a royalty-financing facility with XOMA (US) LLC that provided up to $10 million in non-dilutive capital during 2023. The structure exchanges tiered royalties on future DSUVIA and Niyad commercial sales for upfront clinical-trial funding, insulating existing shareholders from the dilution typical of development-stage biotech firms.
What is Niyad and why does it have Breakthrough Device Designation?
Niyad is a nafamostat mesylate regional anticoagulant designed to be infused into the extracorporeal dialysis circuit to prevent clotting without systemic anticoagulation effects. The FDA granted Breakthrough Device Designation because the product addresses an unmet need for patients at elevated bleeding risk during renal replacement therapy. This designation accelerates regulatory review.
Who leads investment and strategic decisions at Talphera?
Vincent J. Angotti serves as CEO and has led the firm through its 2023 rebrand from AcelRx, the reverse stock split, and the XOMA royalty facility negotiation. As a publicly traded company without a family-office structure, investment decisions reside with the board and executive management team, not a single-family principal.
Does Talphera operate as a family office?
No. Talphera is a publicly traded commercial-stage biopharmaceutical company on Nasdaq (TLPH). It has no connection to a single-family office, multi-family office, or private wealth-management structure. Its capitalization comes from public equity markets and royalty-based debt facilities, not family or personal wealth.
What occurred during the AcelRx-to-Talphera rebrand?
In January 2023, AcelRx Pharmaceuticals changed its corporate name to Talphera, Inc. The rebrand coincided with a strategic pivot emphasizing Niyad's device regulatory pathway and a simplified capital structure. The DSUVIA commercial organization had already been downsized in 2022 as the firm shifted from direct field-force selling to business-development-led partnerships.
How does Talphera avoid the outpatient opioid controversy?
DSUVIA's FDA label restricts administration to certified medically supervised healthcare settings — it is not available for pharmacy dispensing or patient self-administration. This supervised-use restriction, combined with the drug's single-unit-dose packaging, removes the diversion and addiction-liability concerns associated with conventional outpatient opioid prescribing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: